New 8k:
Northwest Biotherapeutics, Inc. (the “Company”) held an annual meeting of stockholders on January 21, 2018 (the “Annual Meeting”). A quorum was present at the Annual Meeting with 318,702,306 shares of common stock, on an actual and as-converted basis, represented personally or by proxy, which represent approximately 66.19% of the outstanding shares of the Company’s common stock entitled to vote, on an actual and as-converted basis. At the Annual Meeting, the stockholders voted on three matters: (1) the re-election of Mr. Jerry Jasinowski as Class II member of the Board of Directors, (2) approval, on an advisory basis, of the Company’s 2017 executive compensation and (3) ratification of the appointment of Marcum LLP as the Company’s auditors for 2018.
Proposal No. 1. Election of Director.
The stockholders approved the re-election of Mr. Jerry Jasinowski as Class II member of the Board of Directors to serve until the third annual meeting of stockholders following the Annual Meeting. The Class II member was elected at the Annual Meeting as follows:
Broker Non-
For Withheld Abstained
Votes
Jerry Jasinowski 286,542,095 32,160,211 0 0
(89.9%) (10.1%)
Proposal No. 2. Approval of the 2017 Executive Compensation.
The stockholders approved, on an advisory basis, the Company’s 2017 executive compensation, as follows:
Broker Non-
For Against Abstained Votes
Approval of the 2017 Executive 271,582,226 14,987,819 32,132,261 0
Compensation (85.2%) (4.7%) (10.1%)
Proposal No. 3. Ratification of Appointment of Registered Public Accounting Firm.
The stockholders ratified the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2017. Proposal No. 3 was approved at the Annual Meeting as follows:
Broker Non-
For Against Abstained Votes
Ratification of Marcum LLP 290,008,036 3,354,718 25,339,552 0
(91.0%) (1.0%) (8.0%)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NORTHWEST BIOTHERAPEUTICS, INC.
Date: January 25, 2018 By: /s/ Linda Powers
Name: Linda Powers
Title: Chief Executive Officer and Chairman
